• 1
    Deininger, M. W. N., S. G. O”Brien, J. M. Ford, and B. J. Druker. 2003. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol. 21:16371647.
  • 2
    Demetri, G. D., M. von Mehren, C. D. Blanke, A. D. Van den Abbeele, B. Eisenberg, P. J. Roberts, et al. 2002. Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:472480.
  • 3
    Tapper, E. B., D. Knowles, T. Heffron, E. C. Lawrence, and M. Csete. 2009. Portopulmonary hypertension: Imatinib as a novel treatment and the Emory experience. Transplant Proc. 41:19691971.
  • 4
    Moinzadeh, P., N. Hunzelmann, and T. Krieg. 2013. Pharmacology and rationale for imatinib in the treatment of scleroderma. J. Exp. Pharmacol. 5:1522.
  • 5
    Aldin, E. S., F. Mourad, and A. Tfayli. 2012. Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib. Jpn. J. Clin. Oncol. 42:447450.
  • 6
    Khanna, D., R. Saggar, M. D. Mayes, F. Abtin, P. J. Clements, P. Maranian, et al. 2011. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 63:35403546.
  • 7
    Gostout, C. J., T. R. Viggiano, D. A. Ahlquist, K. K. Wang, M. V. Larson, and R. Balm. 1992. The clinical and endoscopic spectrum of the watermelon stomach. J. Clin. Gastroenterol. 15:256263.